↓ Skip to main content

Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes

Overview of attention for article published in Frontiers in Pharmacology, August 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter
7 X users

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes
Published in
Frontiers in Pharmacology, August 2018
DOI 10.3389/fphar.2018.00905
Pubmed ID
Authors

Raúl A. Mejía-Pedroza, Jesús Espinal-Enríquez, Enrique Hernández-Lemus

Abstract

Breast cancer is a major public health problem which treatment needs new pharmacological options. In the last decades, during the postgenomic era new theoretical and technological tools that give us novel and promising ways to address these problems have emerged. In this work, we integrate several tools that exploit disease-specific experimental transcriptomic results in addition to information from biological and pharmacological data bases obtaining a contextual prioritization of pathways and drugs in breast cancer subtypes. The usefulness of these results should be evaluated in terms of drug repurposing in each breast cancer molecular subtype therapy. In favor of breast cancer patients, this methodology could be further developed to provide personalized treatment schemes. The latter are particularly needed in those breast cancer subtypes with limited therapeutic options or those who have developed resistance to the current pharmacological schemes.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 21%
Student > Bachelor 4 10%
Student > Doctoral Student 3 8%
Student > Ph. D. Student 3 8%
Researcher 2 5%
Other 5 13%
Unknown 14 36%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 9 23%
Pharmacology, Toxicology and Pharmaceutical Science 6 15%
Engineering 3 8%
Medicine and Dentistry 2 5%
Computer Science 1 3%
Other 2 5%
Unknown 16 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2018.
All research outputs
#6,195,180
of 23,096,849 outputs
Outputs from Frontiers in Pharmacology
#2,496
of 16,456 outputs
Outputs of similar age
#107,053
of 330,627 outputs
Outputs of similar age from Frontiers in Pharmacology
#51
of 391 outputs
Altmetric has tracked 23,096,849 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 16,456 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,627 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 391 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.